Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Operating Leases (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Operating Leases for 4 consecutive years, with $1.1 million as the latest value for Q3 2024.

  • On a quarterly basis, Operating Leases fell 45.32% to $1.1 million in Q3 2024 year-over-year; TTM through Sep 2024 was $1.1 million, a 45.32% decrease, with the full-year FY2023 number at $1.6 million, down 25.44% from a year prior.
  • Operating Leases was $1.1 million for Q3 2024 at Actinium Pharmaceuticals, down from $1.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.2 million in Q3 2022 to a low of $62000.0 in Q2 2021.
  • A 4-year average of $1.5 million and a median of $1.8 million in 2023 define the central range for Operating Leases.
  • Biggest YoY gain for Operating Leases was 0.0% in 2024; the steepest drop was 45.32% in 2024.
  • Actinium Pharmaceuticals' Operating Leases stood at $62000.0 in 2021, then skyrocketed by 3259.68% to $2.1 million in 2022, then dropped by 25.44% to $1.6 million in 2023, then dropped by 26.66% to $1.1 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Operating Leases are $1.1 million (Q3 2024), $1.3 million (Q2 2024), and $2.0 million (Q1 2024).